Journal
CLINICS IN CHEST MEDICINE
Volume 30, Issue 4, Pages 769-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2009.08.009
Keywords
Tuberculosis; Immunotherapeutics; Antituberculous; Chemotherapy; Pulmonary infection; Immunopathology; TB treatment
Categories
Funding
- NIAID NIH HHS [R01 AI054338, R01 AI066046, R01 AI054338-09] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapies have the potential to improve the outcome in all patients with tuberculosis (TB) including those with multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB. Immunotherapy for TB may shorten duration of treatment and reduce pathology in individuals cured by chemotherapy, potentially preventing recurrence. Currently none of the available candidate agents have proof of efficacy for use in MDR-TB or XDR-TB. Further development and evaluation of existing immunotherapeutic agents is required to identify an effective agent that can be used adjunctively with chemotherapy to improve treatment outcomes for drug-susceptible TB, MDR-TB, and XDR-TB. With a range of potential immunotherapeutics, some of which have been produced to good manufacturing practice (GMP) standards and are registered for other indications in humans, the immunotherapy option should no longer be ignored.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available